Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 7;16(4):e0247807. doi: 10.1371/journal.pone.0247807

Ultrasound-guided fine needle aspiration cytology and ultrasound examination of thyroid nodules in the UAE: A comparison

Suhail Al-Salam 1, Charu Sharma 2, Maysam T Abu Sa’a 3, Bachar Afandi 4, Khaled M Aldahmani 4, Alia Al Dhaheri 5, Hayat Yahya 5, Duha Al Naqbi 5, Esraa Al Zuraiqi 5, Baraa Kamal Mohamed 5, Shamsa Ahmed Almansoori 5, Meera Al Zaabi 5, Aysha Al Derei 5, Amal Al Shamsi 2, Juma Al Kaabi 2,*
Editor: Peter Dziegielewski6
PMCID: PMC8026079  PMID: 33826647

Abstract

Background

Thyroid nodules are a common clinical finding and most are benign, however, 5–15% can be malignant. There is limited regional data describing the accuracy of ultrasound-guided fine needle aspiration (FNA) cytological examination compared to ultrasound examination of thyroid in patients who have undergone thyroid surgery.

Methods

A retrospective analysis of ultrasonographic (US) reports, FNA cytology reports and histopathology reports of 161 thyroid nodules presented at the endocrine center at Tawam hospital in Al Ain city, the United Arab Emirates during the period 2011–2019 was performed. US reports and images with FNA cytopathology reports and slides were reviewed by an independent radiologist and pathologist.

Results

In total, 40 nodules were reported as benign by US examination, while very low suspicious, low suspicious, intermediate suspicious and highly suspicious categories were reported in 21, 41, 14 and 45 nodules respectively. In addition, 68 nodules were reported as benign (Bethesda category II), while atypical follicular cells of unknown significance (Bethesda category III), follicular neoplasm (Bethesda category IV), suspicious for malignancy (Bethesda category V), and malignant (Bethesda category VI) categories were reported in 33, 9, 24 and 27 nodules respectively. The risk of malignancy for US benign nodules was 5%, while the risks of malignancy in very low suspicious, low suspicious, intermediate suspicious and highly suspicious nodules were 52%, 36%, 100% and 87%, respectively. The risk of malignancy for Bethesda category II was 3%, while the risks of malignancy in category III, IV, V and VI were 58%, 67%, 96% and 100%, respectively.

Conclusion

Thyroid FNA cytological examination and ultrasonography are key tools in predicting malignancy in thyroid nodules. Thyroid nodules with the diagnosis of Bethesda category III & IV run a high risk of malignancy thus more vigilance is required.

Introduction

Nodules in thyroid glands are a common clinical finding [1]. Most thyroid nodules are benign, however, 5–15% may be malignant [1]. Thyroid nodules are more commonly seen in females and their incidence is increased with age and iodine deficiency. The use of ultrasound has improved the rate of detection and has led to a higher incidence rate. A significant number of thyroid nodules have been detected at autopsy [2]. Since the vast majority of thyroid nodules are asymptomatic, regular clinical and ultrasound (US) follow-up are essential to determine the need for further fine needle aspiration (FNA) cytology study [3]. US stratification tends to lead the treating physician to request FNA of the thyroid gland.

The Bethesda system for reporting thyroid cytopathology (TBSRTC) is the recommended methodology in reporting FNA cytology [4, 5]. TBSRTC consists of six categories and each category carries a certain risk of malignancy.

Till now, clinical management of the Bethesda category III atypia of undetermined significance (AUS) or Follicular lesion of undetermined significance (FLUS) and category IV follicular neoplasm/suspicion for a follicular neoplasm pose a great challenge between observation and follow-up with FNA with or without molecular markers, based on availability, or surgery.

Thyroid US is an important tool for the assessment of thyroid nodules. It can determine the size, site, shape, consistency, contour, circumscription, and extension to adjacent thyroid parenchyma. The American Thyroid Association (ATA) guidelines for ultrasound examination has introduced five US patterns of thyroid nodules. The benign, very low suspicion, low suspicion, intermediate suspicion, and high suspicion patterns [3]. Each category has a certain risk of malignancy [3].

There is limited regional data of thyroid nodules describing the accuracy of US thyroid in comparison to FNA of the thyroid in patients who underwent thyroid surgery. In this study, we will determine the risk of malignancy of each category in TBSRTC and ATA guidelines for thyroid sonography of thyroid nodules presented to the endocrine division at a tertiary care hospital. We will also compare the accuracy of predicting malignancy between US ATA highly suspicious reports and Bethesda category VI (malignant) reports.

Materials and methods

A retrospective analysis was performed on patients with thyroid nodules at Tawam Hospital, Al Ain, UAE from 2011 to 2019. All patients underwent US examination, US-guided FNA cytology examinations and followed by thyroidectomy. A total number of 161 cases were found with mean age ± SE of 39.95 ± 11.49 years.

Ethical approval

The protocol of the present study conformed to the ethical guidelines of the World Medical Association, Declaration of Helsinki, and was approved by Al Ain Medical District Human Research Ethics Committee (THREC-438). Patients or their caregivers signed a written consent allowing the use of their anonymized material for research purposes.

Data collection

A chart review was performed and data were collected from medical records at Tawam Hospital, for the period 2011 to 2019. All adult patients (i.e., aged ≥18 years) with thyroid nodules who underwent FNA cytology and US examination for single or multiple thyroid nodules and were subjected to thyroid surgery were included in this study. The collected data including demographics, FNA reports, histopathology reports, and US reports were collected from the patients’ files in the electronic medical record system.

The US thyroid images were reviewed by an independent radiologist. The FNA thyroid and the histopathology specimen were reviewed by an independent pathologist.

Inclusion criteria

  1. Adult patients with thyroid nodule detected clinically and confirmed by US examination and who underwent FNA cytology examination followed by thyroidectomy.

  2. Adult patients with incidental thyroid nodules detected and confirmed by US examination and who underwent FNA cytology examination followed by thyroidectomy.

Exclusion criteria

  1. Adult patients who have thyroid nodules and underwent US and FNA cytology examination but did not have thyroidectomy with histopathologic diagnosis.

  2. Adult patients with incomplete data were not included in this study.

  3. Adult patients with non-diagnostic category in the Bethesda scoring system were also excluded from this study because they were not followed by thyroidectomy.

  4. Adult patients with previous thyroid surgery prior to FNA or US.

  5. Adult patients who have FNA or US reports of more than one year from the date of surgery.

  6. Adult patients with thyroidectomy that have non-thyroid follicular cells associated pathology.

Ultrasound assessment and categories

Ultrasound reports and images of 161 patients with thyroid nodules were retrieved from Tawam Hospital patients’ files. Thyroid nodules were classified according to American thyroid association (ATA) guidelines of US assessment of thyroid nodules [3]. The US results were then compared with histopathology results.

Thyroid nodules were categorized according to the following:

  • Benign: Purely cystic nodules (no solid component).

  • Very low suspicion: Spongiform or partially cystic nodules without any of the US features described in low, intermediate, or high suspicion patterns.

  • Low suspicion: Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric solid areas.

  • Intermediates suspicion: Hypoechoic solid nodule with smooth margins.

  • Highly suspicious: Solid hypoechoic nodule or Solid hypoechoic component of a partially cystic nodule with one or more of the following features: irregular margins (infiltrative, microlobulated), microcalcifications, taller than wide shape, rim calcifications with small extrusive soft tissue component, evidence of extra-thyroid extension

Fine needle aspiration cytology assessment and categories

Reports and slides of 161 patients with thyroid nodules were retrieved from Tawam Hospital patients’ files. FNA adequacy is defined as the presence of at least five groups of follicular cells each with 12 cells. The FNA results were then compared with histopathology results.

Thyroid nodules were classified according to The Bethesda reporting system for thyroid cytopathology and were scored according to the following [3]:

  1. Non-Diagnostic or unsatisfactory

  2. Benign: A non-neoplastic FNA CYTOLOGY includes colloid nodules, chronic autoimmune thyroiditis and adenomatoid nodules.

  3. Atypia of undetermined significance (AUS) or Follicular lesion of undetermined
    1. significance (FLUS)
  4. Follicular neoplasm/suspicious for follicular neoplasm

  5. Suspicious for malignancy

  6. Malignant

The non-diagnostic or unsatisfactory (category I) was excluded from this study because there were no thyroid surgery or histopathological examination.

Histological classification

The histologic diagnosis of nodules was classified into 3 categories:

  1. Non-neoplastic conditions: Adenomatous nodules, colloid nodules, lymphocytic thyroiditis

  2. Follicular adenoma

  3. Carcinoma

Data analysis

The data was extracted from the FNA cytology, USS and histopathology reports of the patients who have undergone surgery during the study period. All data was analyzed using the Statistical Package for the Social Sciences (version 20.0) using descriptive statistics. The chi-square test with Yates correction was used to compare between frequencies. Data are presented as mean ± standard error of the mean. P values < 0.05 were considered significant.

The accuracy test was done using the following formula:

Accuracy=Truepositive+Truenegative/Truepositive+Truenegative+Falsepositive+Falsenegative.

Histological diagnosis was taken as the gold standard and the FNA cytology and US diagnoses were compared to it.

Results

In total, 161 cases of thyroid nodules were studied. The mean age was 39.95 ± 11.49. Females (137) constitute 85% while males (24) constitute 15% of the cases. The mean BMI was 29.19 ± 6.32.

Thyroid ultrasound study

In total, 40 (24.8%) nodules were reported as benign, while very low suspicious, low suspicious, intermediate suspicious, and highly suspicious comprised 21 (13%), 41 (25.6%), 14 (8.7%) and 45 (27.9%), respectively Table 1.

Table 1. Ultrasound categories of 161 thyroid nodules according to American thyroid association guidelines.

Ultrasound Category Number Percent
Benign 40 24.8
Very low suspicion 21 13.0
Low suspicion 41 25.6
Intermediate suspicion 14 8.7
Highly suspicion 45 27.9
Total 161 100

Thyroid fine needle aspiration cytology

In total, 68 (42.2%) nodules were reported as benign (Bethesda category II), while AUS/FLUS (Bethesda category III), Follicular neoplasm/suspicious for follicular neoplasm

(Bethesda category IV), suspicious for malignancy (Bethesda category V), and malignant (Bethesda category VI) comprised 33 (20.5%), 9 (5.5%), 24 (15%) and 27 (16.8%), respectively Table 2.

Table 2. The Bethesda reporting system for thyroid cytopathology categories of 161 thyroid nodules.

Bethesda Category Number Percent
    Benign 68 42.2
    AUS/FLUS 33 20.5
Follicular neoplasm/suspicious for follicular neoplasm 9 5.5
    Suspicious for malignancy 24 15
    Malignant 27 16.8
    Total 161 100

Histopathologic diagnosis of thyroid nodules

In total, 73 (38.4%) nodules were reported as non-neoplastic nodules (Adenomatous nodules, colloid nodules, lymphocytic thyroiditis), while follicular adenomas and carcinomas comprised 10 (6.1%) and 78 (55.5%), respectively Table 3.

Table 3. Histopathologic diagnosis of 161 thyroid nodules.

Histologic diagnosis Number Percent
Non-neoplastic nodules 73 45.3
Follicular adenoma 10 6.3
Thyroid carcinoma 78 48.4
Total 161 100%

Correlation between Ultrasonographic category and risk of malignancy

The risk of malignancy for US benign category was 5%, while very low suspicious, low suspicious, intermediate suspicious, and highly suspicious were 52%, 36%, 100% and 87%, respectively, Table 4.

Table 4. Correlation between ultrasonographic category and risk of malignancy.

US category Non-Neoplastic Nodule % Follicular adenoma % Carcinoma %
Benign 90 5 5
Very low suspicion 43 5 52
Low suspicion 54 10 36
Intermediate suspicion 0 0 100
Highly suspicious 11 2 87

Correlation between Bethesda categories and risk of malignancy

The risk of malignancy for Bethesda category II was 3%, while the risk of malignancy in category III, IV, V and VI were 58%, 67%, 96% and 100%, respectively Table 5.

Table 5. Correlation between Bethesda categories and risk of malignancy.

Bethesda category Non-Neoplastic Nodule Follicular adenoma Carcinoma
% % %
II 97 0 3
III 24 18 58
IV 22 11 67
V 0 4 96
VI 0 0 100

Comparison between Ultrasound and FNA cytology risk of malignancy

There was no significant difference between the benign category in the TBSRTC and ATA US reporting systems. The chi-square statistic was 0.4631. The p-value was 0.4. The chi-square statistic with Yates correction was 0.1. The p-value is 0.75.

There was a significant difference in the risk of malignancy between the Bethesda category VI (malignant) and the Ultrasound highly suspicious category. The chi-square statistic was 13.9. The p-value was 0.0002. The chi-square statistic with Yates correction was 11.85. The p-value was 0.0006.

Correlation between Bethesda Categories III and IV and histologic types of carcinoma

Eighteen thyroid nodules with a cytopathologic diagnosis of category III had a histologic diagnosis of thyroid carcinoma. Interestingly, 41% (7) of them were microcarcinoma, 22% (4) were follicular variant PTC, 11% (2) were follicular carcinoma and 28% (5) were classic PTC with a tumor size pT1b (>1cm<2cm) Table 6.

Table 6. Correlation between Bethesda category III and IV and histologic types of carcinoma.

Bethesda Category Follicular Carcinoma Follicular variant PTC Microcarcinoma Classic Papillary carcinoma Classic PTC
pT1a (>1cm<2cm) pT1b (>1cm<2cm)
III 2 4 7 5
IV 0 2 3 1
Total 3 6 10 7

Moreover, 6 thyroid nodules with a cytopathologic diagnosis of Category IV, have a histologic diagnosis of thyroid carcinoma. Interestingly, 50% (3) of them were microcarcinoma, 34% (2) were follicular variant PTC, and 16% (1) were classic PTC with a tumor size pT1b (>1cm<2cm) Table 6.

Comparison between accuracy of predicting malignancy between Bethesda category VI and US ATA highly suspicious category

Accuracy of FNA reports Bethesda category VI = 27+0/ 27+0+0+0 = 1 = 100%

Accuracy of US ATA reports highly suspicious category = 39+0/ 39+0+6+0 = 0.87 = 87%

FNA cytological reporting of Bethesda category VI is significantly more accurate than US ATA reporting highly suspicious category, Chi-square with Yates’ correction 11.85, p = 0.0006.

Discussion

Many studies have considered FNA cytology as the gold standard in analyzing thyroid nodules as well as outlining the future management of patients with thyroid nodules [612]. However, indeterminate cytopathological diagnoses, Bethesda category III and IV, creates a problem in determining the appropriate method of management of patients with thyroid nodules.

We have shown 68 (42.2%) of FNA cytology have been reported as benign (Bethesda category II). Of these 2 were found to be malignant on histologic examination, giving a 3% risk of malignancy. This is mainly related to miss sampling of the area of carcinoma with FNA in thyroid nodules from clinically or radiological diagnosed multinodular goiter, especially, when there is no clinical or radiologic suspicion of malignancy. This rate is close to the 3.1%, 3.7%, 5.6%, 6% and 8% previously reported [1115]. The risk of malignancy was originally reported for this category in the initial BSRTC definition at 0%–3% [16, 17].

We have also shown 33 (20.5%) of the FNA cytology being reported as AUS/FLUS (Bethesda category III). Of these 18 (54.5%) were reported malignant on histopathological examination and were either microcarcinoma or follicular variant PTC, or follicular carcinoma or classic PTC pT1b (>1cm<2cm) (Table 6). Interestingly, the reported malignancy rates for this category vary widely, from 50% [11, 12] to 69% [13] and 79% [18], while rates were much lower (10–30%) in the BSRTC definition [16, 17]. The lower rate of malignancy in category III according to the BSRTC definition report was probably due to the high number of cases included in their study as compared with the current study.

Nine (5.5%) cases of FNA cytology were reported as follicular neoplasm/suspicious for follicular neoplasm (Bethesda category IV). Of those, 6 (67%) were reported malignant on histopathological examination and were either microcarcinoma or follicular variant PTC (Table 6). This high rate was also reported by Lee et al. study 79% [18]. A lower rate was also seen in Mufti et al. 20% [11], and 52% in Zarin et al. study [12]. A lower rate (25–40%) has also been reported according to the BSRTC definition [16, 17]. The lower rate of malignancy in category IV in the BSRTC definition report is probably due to the high number of cases included in their study when compared with the current study.

The two indeterminate categories of III & IV are reported in the BSRTC definition report in about 15–30% and 25–40% of nodules respectively [16, 17]. They pose clinical challenges for endocrine physicians [1921]. While the majority will have benign nodules, the malignancy risk is not trivial and typically triggers for additional investigations or treatment [20, 22]. Current strategy for such patients includes observation, repeat FNA with or without molecular markers, core needle biopsy or surgery (lobectomy or total thyroidectomy). As clear guidance on the best strategy is lacking, it largely depends on patient and or physician preference and experience, availability of molecular markers, cost, and the surgical expertise. Findings from US can also help in that nodules with suspicious lesions are typically managed surgically while those lacking features of malignancy might be observed periodically with serial US assessments [22]. In the current study, a high rate of risk of malignancy in these two categories has been identified, suggesting the requirement for a strict follow up of patients diagnosed as Bethesda III and IV with ultrasound guided FNA cytologic examination. The high rate of malignancy in Bethesda category III and IV seen in the current study could be related to the fact that many cases are found to be either microcarcinoma, that can easily be miss sampled, or follicular variant PTC, or follicular carcinoma (Table 6), which can easily be under diagnosed on FNA cytological examination either because of the lack of nuclear features of PTC or due to the difficulty in discriminating benign from malignant follicular cells proliferation as both may show increased cellularity and mild nuclear pleomorphism. In addition, in many follicular neoplasms, capsular invasion is needed to make the diagnosis of malignancy, a feature that is impossible to see in FNA cytological preparation.

We believe that FNA cytology is rather a screening tool more than a definite diagnostic tool and definite diagnosis can only be made by tissue biopsy. So it is very helpful in categorizing thyroid nodules according to their probable risk of malignancy from benign (least risk of malignancy) at one end to malignant at the other end of the spectrum. This makes the TBSRTC approach very appropriate in cytological categorization, management and follow-up of thyroid nodules. Each TBSRTC category has a diagnostic criteria and cytopathologists are keen to follow these criteria. Although, cytopathologists would prefer false negative rather than false positive diagnosis in thyroid FNA of difficult and ambiguous smears, but they are limited by the Bethesda cytopathological criteria of each category, sample adequacy, sample representability and sample processing. The way of smearing FNA samples on glass slides requires expertise and inadequate spread of lesional cells can affect the appearance of the cells and may affect the diagnosis. The cytopathological diagnostic criteria depends entirely on the nuclear features and if the nuclei are not visualized clearly in the smear, it will be difficult to come up with an appropriate diagnosis.

Twenty-four (14.6%) cases of FNA cytology were reported as suspicious for malignancy (Bethesda category V). Of those 23 were reported malignant by histopathological examination giving a 96% risk of malignancy. This is similar to what has been reported by Zarif et al. (95.6%) [12], and higher than was reported by the BSRTC report [16, 17]. The higher rate of Bethesda category V reported in the current study may be related to sampling issues and variable experience of aspiration techniques as well as differences in interpretation of findings. However, these differences should have no clinical consequences because the BSRTC recommendation for management of patients in category V and category VI is surgery.

Interestingly, 27 (16.5%) cases of FNA cytology were reported as malignant and all of them were proved to be malignant on histopathological examination making a 100% risk of malignancy of category VI, the same result reported by Mufti et al. [11], and similar to the risk of malignancy in the BSRTC report (97%–99%) [16, 17].

Thyroid US has been commonly used to identify the risk of malignancy in thyroid nodules, and help in making decisions on whether FNA is indicated or not. Previous studies have reported that several US features are associated with thyroid cancer and the majority are related to PTC [3].

We have shown 40 (24.8%) thyroid nodules have been reported as benign. Of these 2 were found malignant on histologic examination, giving a 5% risk of malignancy. This rate is significantly higher than the <1% previously reported [2226]. This discrepancy is possibly due to the differences in samples and presence of microcarcinoma. We have also shown 21 (13%) of nodules reported are in the very low suspicious category by US. Of these 11 (52%) were reported malignant on histologic examination. This rate is significantly higher than the <3% previously reported [2226]. The higher rate of malignancy in this category may be due to the difficulty of discriminating between benign and malignant US features.

Forty-one (25.6%) nodules were reported as low suspicious by US. Of these 15 were reported as malignant on histologic examination equating to a 36% risk of malignancy. This rate is significantly higher than the 5–10% previously reported [2226]. The high rate of malignancy in this category may be due to the difficulty of discriminating between benign and malignant US features.

Fourteen (8.7%) nodules were reported as intermediate suspicious by US. Of those 14 were reported malignant on histologic examination equating to a 100% risk of malignancy. This rate is significantly higher than the 10–20% previously reported. [2226]. The higher risk rate of malignancy of this US category in the current study is possibly related to a high threshold of suspicion by the radiologist in interpreting US images of these thyroid nodules.

Forty-five (27.9%) nodules were reported as highly suspicious by US. Of those 39 were reported malignant on histologic examination equating to an 87% risk of malignancy. This rate is within the range of previously reported risk of malignancy in this category 70–90% [2226].

The comparison in the risk of malignancy shows significant differences between TBRSTC category VI and ATA US highly suspicious category. There is no evidence of false positive or false negative diagnosis in all FNA cytology reports of TBRSTC category VI (malignant) and the accuracy was 100%, while the accuracy of ATA US highly suspicious category was 87%. This suggests that FNA cytology is more accurate than US in predicting malignant thyroid carcinomas in the present study.

The limitations of this study include sample size as well as being a retrospective study. However, the studied material included all cases with thyroid nodules that fulfill the inclusion criteria in our tertiary care hospital during the period 2011–2019 and there is limited regional data comparing the risk of malignancy in thyroid nodules between FNA cytology and US examination [11, 27]. We have excluded TBRSTC category I from our study because they are non-diagnostic and the patients did not undergo thyroid surgery.

Conclusions

Thyroid FNA cytological examination and US are key tools in predicting malignancy in thyroid nodules. Thyroid nodules with the diagnosis of Bethesda category III & IV run a high risk of malignancy thus more vigilance is required.

Acknowledgments

We would also like to thank Dr. Klaus Van Gorkom, Department of Radiology, College of Medicine & Health Sciences, UAE University for his support in this project. We would also like to thank the Laboratory Medicine Department, Anatomic Pathology Division at Tawam Hospital, Al Ain City, UAE, for their support in this project. We would like thank Prof Chris Howarth for English editing.

Data Availability

All relevant data are within the paper. Further demographic or detailed patient characteristics can be available upon a reasonable request. Al Ain Medical District Human Research Ethics Committee (AAMDHREC) has imposed these restrictions. Requests for the data can be sent to Dr Rami Beiram: Assistant Dean for Research and Graduate Studies College of Medicine and Health Sciences P.O.Box: 15551, Al Ain, UAE Email: rbeiram@uaeu.ac.ae Tel: +971 3 713 7174.

Funding Statement

This work was supported by research grant (SURE Grant 31M352 and 31 M355), from Research Office, UAE University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received no specific funding for this work.

References

  • 1.Hegedus L. The thyroid nodule. New England Journal of Medicine. 2004; 351:1764–71. 10.1056/NEJMcp031436 [DOI] [PubMed] [Google Scholar]
  • 2.Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocrinology Reviews 2003; 24:102–32. 10.1210/er.2002-0016 [DOI] [PubMed] [Google Scholar]
  • 3.Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015;26(1):1–133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009; 19(11):1159–65. 10.1089/thy.2009.0274 [DOI] [PubMed] [Google Scholar]
  • 5.Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, et al. The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel. Acta Cytology. 2016;60(5):399–405. [DOI] [PubMed] [Google Scholar]
  • 6.Machała E, Sopiński J, Iavorska I, Kołomecki K. Correlation of Fine Needle Aspiration Cytology of Thyroid Gland with Histopathological Results. Pol Przegl Chir. 2018; 21;90(6):1–5. 10.5604/01.3001.0012.4712 [DOI] [PubMed] [Google Scholar]
  • 7.Melany M, Chen S. Thyroid Cancer: Ultrasound Imaging and Fine-Needle Aspiration Biopsy. Endocrinology and Metabolism Clinics of North America 2017;46(3):691–711 10.1016/j.ecl.2017.04.011 [DOI] [PubMed] [Google Scholar]
  • 8.Singaporewalla RM, Hwee J, Lang TU, Desai V. Clinico-pathological Correlation of Thyroid Nodule Ultrasound and Cytology Using the TIRADS and Bethesda Classifications. World Journal of Surgery. 2017;41(7):1807–11. 10.1007/s00268-017-3919-5 [DOI] [PubMed] [Google Scholar]
  • 9.Gupta M, Gupta S, Gupta VB. Correlation of fine needle aspiration cytology with histopathology in the diagnosis of solitary thyroid nodule. Journal of Thyroid Research. 2010; 18; 379051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sahin M, Gursoy A, Tutuncu NB, Guvener DN. Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clinical Endocrinology (Oxf). 2006;65(4):514–8. 10.1111/j.1365-2265.2006.02625.x [DOI] [PubMed] [Google Scholar]
  • 11.Mufti ST, Molah R. The bethesda system for reporting thyroid cytopathology: a five-year retrospective review of one center experience. Int J Health Sci (Qassim). 2012;6(2):159–73. 10.12816/0005991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zarif HA, Ghandurah SE, Al-Garni MA, Binmahfooz SK, Alsaywid BS, Satti MB. Thyroid Nodules Cytopathology Applying the Bethesda System with Histopathological Correlation. Saudi Journal of Medicine & Medical Sciences 2018;6(3):143–148. 10.4103/sjmms.sjmms_178_17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Park JH, Yoon SO, Son EJ, Kim HM, Nahm JH, Hong S, et al. Incidence and malignancy rates of diagnoses in the Bethesda system for reporting thyroid aspiration cytology: An institutional experience. Korean Journal of Pathology 2014; 48:133–9. 10.4132/KoreanJPathol.2014.48.2.133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: A meta-analysis. Acta Cytology. 2012; 56:333–9. 10.1159/000339959 [DOI] [PubMed] [Google Scholar]
  • 15.Wu HH, Rose C, Elsheikh TM. The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagnostic Cytopathology 2012; 40:399–403. 10.1002/dc.21754 [DOI] [PubMed] [Google Scholar]
  • 16.Cibas ES, Ali SZ. NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology. American Journal of Clinical Pathology 2009; 132:658–65. 10.1309/AJCPPHLWMI3JV4LA [DOI] [PubMed] [Google Scholar]
  • 17.Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341–1346. 10.1089/thy.2017.0500 [DOI] [PubMed] [Google Scholar]
  • 18.Lee K, Jung CK, Lee KY, Bae JS, Lim DJ, et al. Application of Bethesda system for reporting thyroid aspiration cytology. Korean Journal of Pathology 2010; 44:521–7. [Google Scholar]
  • 19.Huhtamella R, Kholová I. Thyroid Bethesda Category AUS/FLUS in Our Microscopes: Three-Year-Experience and Cyto-Histological Correlation. Cancers (Basel). 2019; 28;11(11). 10.3390/cancers11111670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Maity P, Jha AK, Sengupta M, Basu K, Chatterjee U, et al. Thyroid Bethesda Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance (AUS/FLUS): A Heterogenous Group. Journal of Cytology 2019;36(4):200–204. 10.4103/JOC.JOC_160_18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Chirayath SR, Pavithran PV, Abraham N, Nair V, Bhavani N, et al. Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAFV600E Mutation. Indian Journal of Endocrinology and Metabolism 2019;23(3):278–81. 10.4103/ijem.IJEM_635_18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Valderrabano P, McGettigan MJ, Lam CA, Khazai L, Thompson ZJ, Chung CH, et al. Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk Stratification. Thyroid. 2018;28(8):1004–1012. 10.1089/thy.2018.0085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. Journal of Clinical Endocrinology and Metabolism 2009; 94:1748–51. 10.1210/jc.2008-1724 [DOI] [PubMed] [Google Scholar]
  • 24.Tae HJ, Lim DJ, Baek KH, Park WC, Lee YS, et al. Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid 2007; 17:461–66. 10.1089/thy.2006.0337 [DOI] [PubMed] [Google Scholar]
  • 25.Lam CA, McGettigan MJ, Thompson ZJ, Khazai L, Chung CH, et al. Ultrasound characterization for thyroid nodules with indeterminate cytology: inter-observer agreement and impact of combining pattern-based and scoring-based classifications in risk stratification. Endocrine. 2019;66(2):278–87. 10.1007/s12020-019-02000-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Grani G, Lamartina L, Biffoni M, Giacomelli L, Maranghi M, et al. Sonographically Estimated Risks of Malignancy for Thyroid Nodules Computed with Five Standard Classification Systems: Changes over Time and Their Relation to Malignancy. Thyroid. 2018;28(9):1190–97. 10.1089/thy.2018.0178 [DOI] [PubMed] [Google Scholar]
  • 27.Alseddeeqi E, Baharoon R, Mohamed R, Ghaith J, Al-Helali A, Ahmed LA. Thyroid malignancy among patients with thyroid nodules in the United Arab Emirates: a five-year retrospective tertiary Centre analysis. Thyroid Res. 2018. November 30;11:17. 10.1186/s13044-018-0061-x [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Peter Dziegielewski

1 Jan 2021

PONE-D-20-23164

Ultrasound-guided fine needle aspiration cytology and ultrasound examination of thyroid nodules in the UAE: a comparison

PLOS ONE

Dear Dr. Kaabi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 15 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Peter Dziegielewski, MD, FRCSC

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following at the end of your manuscript:

'Funding

This work was supported by research grant (SURE Grant 31M352 and 31 M355), from Research Office, UAE University. The funders had no roles in study design, data collection and analysis, decision to publish, or prepare of the manuscript.'

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

a. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

'The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.'

b. Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript entitled "Ultrasound-guided fine needle aspiration cytology and ultrasound examination of thyroid nodules in the UAE: a comparison" reports a very interesting and important clinical problem. However, the relationship between US pattern, FNA diagnosis and histopathological structure of thyroid nodules is a subject of intensive research in many laboratories, and the issue investigated in this research is known from dozens of similar studies.

This research has serious flaws.

Firstly, the number of cases was small (164 patients treated between 2011-2019), and further studies with larger sample sizes are needed. What is particularly odd, the number of patients equals the number of lesions/nodules examined. Did all of the patients only have one nodule?

Secondly, there was selection bias, because patients included in this study underwent FNA and surgery, indicating that patients were not representative of the whole population.

Thirdly, this was a single-center, retrospective study, which may have reduced the statistical significance.

For instance, the reason of malignancy rate, especially in III and IV categories, being higher than that reported in TBSRTC, may be that cytopathologists from Tawam Hospital did not properly apply the TBSRTC classification criteria. Similarly, the high rate of malignances in III and IV categories, has been reported by Lee (Lee K, Jung CK, Lee KY, Bae JS, Lim DJ, et al. Application of Bethesda system for reporting thyroid aspiration cytology. Korean Journal of Pathology 2010; 44:521–7) and Park (Park JH, Yoon SO, Son EJ, Kim HM, Nahm JH, Hong S, et al. Incidence and malignancy rates of diagnoses in the Bethesda system for reporting thyroid aspiration cytology: An institutional experience. Korean Journal of Pathology 2014; 48:133–90). However, the explanation of this phenomenon given by Lee et al. is the pathologists’ mistake during classification to these categories. Different explanation was provided by Park. From the perspective of these authors there are two possible reasons for differences between malignancy rate in Korean study and official TBSRTC rates: “First, although the BSRTC guidelines recommend that patients with categories I or III diagnoses have a repeat FNA, in Korea, patients who have thyroid nodules that are strongly suspicious for malignancy in a clinical aspect undergo surgery without a repeat FNA, but a frozen section examination may be performed. Second, Korean patients tend to be more concerned about false positive results than false negative results, which may pressure cytopathologists to underdiagnose FNA cases to avoid making false positive diagnoses”.

Another surprising finding is the number of misdiagnosed cases of classic papillary carcinoma in III and IV categories in cytological examination – 16 out of 24 carcinomas in the group of 42 patients. This indicates that prior to possible repeated publication, a cytological evaluation of these smears, done by highly experienced specialists in thyroid cytopathology, should be conducted.

Minor Essential Revisions

Errors in abundances of groups in tables, and between tables 5 and 6.

Reviewer #2: This study was done in a single hospital in UAE, yielding 161 patients who were operated for thyroid nodules after undergoing both ultrasound and ultrasound guided fine needle aspiration cytology in a period of 8 years (from 2011-2019). It then proceeded to compare the results of each pre operative diagnostic examination with the final histopathologic diagnosis. Not unexpectedly, ultrasound-guided FNA cytology had a higher accuracy rate than ultrasound alone in identifying malignancies. They then proceeded to compare their findings with those of studies in Saudi Arabia and Turkey and found similar results with respect to higher BSRTC or ATA categories turning out malignant. Of concern was their finding that nodules found benign or low suspicious by ultrasound turned out malignant in 5% and 36%, respectively.

The main limitation of this study is that the sample is restricted to the retrospective review of surgical patients only. Thus it is impossible to evaluate the true accuracy of both diagnostic assessments and to apply its results to the majority of non-operative patients with clinically apparent thyroid nodules. Ideally, sensitivity, specificity and accuracy are determined by applying both the test being evaluated and the reference standard on a group of patients regardless of the test result. In this study, the decision to operate on these patients with nodules would have probably been based on the results of either one or both tests, thus biasing the study.

Because of the inherent limitation of their study design the authors must be careful not to apply analytical tools which are more commonly used for diagnostic validation studies. Their conclusions must likewise be tempered by this limitation.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Jose M. Acuin

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 7;16(4):e0247807. doi: 10.1371/journal.pone.0247807.r003

Author response to Decision Letter 0


3 Feb 2021

Response to Reviewers’ comments

Reviewer 1

Many thanks for your valuable comments. Your comments are herein addressed point by point. We agree with you that there are published papers addressing similar issue, but nothing has been published from this part of the world. In this work, we would like to share our experience in FNA cytology and US of thyroid nodules with the international scientific community.

1. The number of cases was small (164 patients treated between 2011-2019), and further studies with larger sample sizes are needed.

Response to reviewer comment

We agree with you that sample size was small. This point has been mentioned in the discussion as a limitation of this study. These are all the cases that were diagnosed by thyroid FNA cytology and US and were followed by surgery during the period 2011-2019. Tawam hospital is a tertiary care center and the main oncology center in the UAE; hence, most of the cases were referred to this hospital from different parts of the country.

2. What is particularly odd, the number of patients equals the number of lesions/nodules examined. Did all of the patients only have one nodule?

Response to reviewer comment

Not all the patients have one nodule. Based on the clinical and US findings, the FNA was done on the most suspicious thyroid nodule, which was followed by histopathological study of the resected specimens. That is why the number of cases have same number of examined nodules by FNA and surgical resection.

3. There was selection bias, because patients included in this study underwent FNA and surgery, indicating that patients were not representative of the whole population.

Response to reviewer comment

We need histopathology to see the risk of malignancy in each Bethesda category as well as in American thyroid association ultrasonographic categories besides measuring the accuracy of each procedure. So, we have studied all the cases that had thyroidectomy following US thyroid and FNA during the period 2011-2019. We think that there was no selection bias in our selection criteria because we include all cases in our center that fulfill the inclusion criteria. Tawam hospital is a tertiary care hospital and the main oncology hospital in the UAE; hence, most of the cases were referred to this hospital from different parts of the country.

4. This was a single-center, retrospective study, which may have reduced the statistical significance.

Response to reviewer comment

We agree with you that this is a retrospective study from one center. Tawam hospital is a tertiary care center and the main oncology center in the UAE; hence, most of the cases were referred to this hospital from different parts of the country. Besides, we would like to share our experience in the diagnosis and management of thyroid nodules with the scientific community.

5. The reason of malignancy rate, especially in III and IV categories, being higher than that reported in TBSRTC, may be that cytopathologists from Tawam Hospital did not properly apply the TBSRTC classification criteria. Similarly, the high rate of malignances in III and IV categories, has been reported by Lee (Lee K, Jung CK, Lee KY, Bae JS, Lim DJ, et al. Application of Bethesda system for reporting thyroid aspiration cytology. Korean Journal of Pathology 2010; 44:521–7) and Park (Park JH, Yoon SO, Son EJ, Kim HM, Nahm JH, Hong S, et al. Incidence and malignancy rates of diagnoses in the Bethesda system for reporting thyroid aspiration cytology: An institutional experience. Korean Journal of Pathology 2014; 48:133–9). However, the explanation of this phenomenon given by Lee et al. is the pathologists’ mistake during classification to these categories. Different explanation was provided by Park. From the perspective of these authors there are two possible reasons for differences between malignancy rate in Korean study and official TBSRTC rates: “First, although the BSRTC guidelines recommend that patients with categories I or III diagnoses have a repeat FNA, in Korea, patients who have thyroid nodules that are strongly suspicious for malignancy in a clinical aspect undergo surgery without a repeat FNA, but a frozen section examination may be performed. Second, Korean patients tend to be more concerned about false positive results than false negative results, which may pressure cytopathologists to underdiagnose FNA cases to avoid making false positive diagnoses”.

Another surprising finding is the number of misdiagnosed cases of classic papillary carcinoma in III and IV categories in cytological examination – 16 out of 24 carcinomas in the group of 42 patients. This indicates that prior to possible repeated publication, a cytological evaluation of these smears, done by highly experienced specialists in thyroid cytopathology, should be conducted.

Response to reviewer comment

We thank you for providing the two references (Lee K et al. and Park JH ) whom have high rates of TBSRTC category III and IV in their studies were similar to ours. We have referred to both studies in the discussion of our manuscript as (reference 17 and 12 respectively).

There are many explanations for the high rate of malignancy TBSRTC category III and IV and we have stated that in the discussion section of our manuscript “The high rate of malignancy in Bethesda category III and IV seen in the current study could be related to the fact that many cases are found to be either microcarcinomas, that can easily be miss-sampled, or follicular variant PTC, or follicular carcinoma (Table 6), which can easily be under diagnosed on FNA cytological examination either because of the lack of nuclear features of PTC or due to the difficulty in discriminating benign from malignant follicular cells proliferation as both may show increased cellularity and mild nuclear pleomorphism. In addition, in many follicular neoplasms, capsular invasion is needed to make the diagnosis of malignancy, a feature that is impossible to see in FNA cytological preparation.

We believe that FNA cytology is rather a screening tool more than a definite diagnostic tool and definite diagnosis can only be made by tissue biopsy. So it is very helpful in categorizing thyroid nodules according to their probable risk of malignancy in a spectrum wise from benign (least risk of malignancy) at one end to malignant at the other end of the spectrum. This makes TBSRTC system very appropriate in cytological categorization, management and follow-up of thyroid nodules. Each TBSRTC category has a diagnostic criteria and cytopathologists are keen to follow these criteria. Although, cytopathologists would prefer false negative more than false positive diagnosis in thyroid FNA of difficult and ambiguous smears, but constantly they are limited by the Bethesda cytopathological criteria of each category, sample adequacy, sample representability and sample processing. The way of smearing FNA samples on glass slides requires certain expertise and inadequate spread of lesional cells can affect the appearance of the cells and may affect the diagnosis. The cytopathological diagnostic criteria depends entirely on the nuclear features and if the nuclei are not visualized clearly in the smear, it will be difficult to have appropriate diagnosis.

Cytopathologists training and experience are also very important limiting factors, and we can assure you that our cytopathologists at Tawam hospital are expert in this field.

This paragraph is added to the discussion.

Minor Essential Revisions

Errors in abundances of groups in tables, and between tables 5 and 6.

Response to reviewer comment

In figure 5 correlation between Bethesda categories and risk of malignancy, all the numbers in the table represent the percentage and are not the number of cases.

While, the number in figure 6 represents the actual number of malignant histology diagnosis in resection specimens of TBSRTC category III and IV cases.

Reviewer #2:

The main limitation of this study is that the sample is restricted to the retrospective review of surgical patients only. Thus, it is impossible to evaluate the true accuracy of both diagnostic assessments and to apply its results to the majority of non-operative patients with clinically apparent thyroid nodules. Ideally, sensitivity, specificity and accuracy are determined by applying both the test being evaluated and the reference standard on a group of patients regardless of the test result. In this study, the decision to operate on these patients with nodules would have probably been based on the results of either one or both tests, thus biasing the study. Because of the inherent limitation of their study design the authors must be careful not to apply analytical tools which are more commonly used for diagnostic validation studies. Their conclusions must likewise be tempered by this limitation.

Response to reviewer comment

Many thanks for your valuable comments. We totally agree with your comments. We have mentioned these limitations in the discussion. In addition, our conclusions will be tempered by this limitation

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Peter Dziegielewski

15 Feb 2021

Ultrasound-guided fine needle aspiration cytology and ultrasound examination of thyroid nodules in the UAE: a comparison

PONE-D-20-23164R1

Dear Dr. Kaabi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Peter Dziegielewski, MD, FRCSC

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for addressing the reviewers comments and critiques.

Reviewers' comments:

Acceptance letter

Peter Dziegielewski

29 Mar 2021

PONE-D-20-23164R1

Ultrasound-guided fine needle aspiration cytology and ultrasound examination of thyroid nodules in the UAE: a comparison

Dear Dr. Kaabi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Peter Dziegielewski

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to PLOS ONE reviewers comments.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper. Further demographic or detailed patient characteristics can be available upon a reasonable request. Al Ain Medical District Human Research Ethics Committee (AAMDHREC) has imposed these restrictions. Requests for the data can be sent to Dr Rami Beiram: Assistant Dean for Research and Graduate Studies College of Medicine and Health Sciences P.O.Box: 15551, Al Ain, UAE Email: rbeiram@uaeu.ac.ae Tel: +971 3 713 7174.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES